Key points from article :
In a major step toward reshaping the future of healthcare, M42—a global AI-powered health company based in Abu Dhabi—has announced a strategic investment and partnership with the UK-based biotech firm Juvenescence. The collaboration, revealed during Abu Dhabi Global Health Week, aims to accelerate the development of AI-enabled therapeutics targeting age-related diseases and other conditions of high unmet medical need, both within the UAE and globally.
The partnership will harness M42’s robust infrastructure in genomics, biobanking, and clinical research, together with Juvenescence’s expertise in drug discovery and development. This alliance will drive the creation of a new pipeline of therapeutics designed to enhance healthspan—the period of life spent in good health—by tackling the root causes of ageing and chronic disease.
M42's newly launched AI Life Sciences Platform is at the core of this initiative, supporting the broader vision of Abu Dhabi to become a world-class hub for life sciences and AI-driven biomedical innovation. By leveraging its vast genomic resources, including the Emirati Genome Project and the Abu Dhabi Biobank, M42 plans to fast-track discoveries and precision medicine advancements.
The partnership will be overseen by a Joint Steering Committee, and further collaborative research with global academic institutions is planned. Dr. Richard Marshall, CEO of Juvenescence, emphasized the transformative potential of the partnership in improving global healthspan through innovative therapies.
